Study Details

Back to Search Results

Study of Ipragliflozin in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02847091

Astellas Study ID

The unique identification code given by the study sponsor.

1941-MA-3054

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Adult Onset Diabetes

Phase

These clinical trials happen after a drug or treatment has been approved for patients to take. Clinical trials in phase 4 usually take place over many years because researchers want to learn about long term use and safety of a drug or treatment.

Phase 4

Age

20 years - 74 years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jul 2016 - Nov 2017

Masking

None (Open Label)

Enrollment number

103

Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Study of Ipragliflozin in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP00010

Kanagawa, Japan

Site JP00007

Gunma, Japan

Site JP00011

Tokyo, Japan

Site JP00013

Tochigi, Japan

Site JP00005

Tochigi, Japan

Site JP00015

Shiga, Japan

Site JP00012

Tokyo, Japan

Site JP00008

Hiroshima, Japan

Site JP00001

Tokyo, Japan

Site JP00004

Osaka, Japan

Site JP00006

Tokyo, Japan

Site JP00003

Mie, Japan

Site JP00014

Tokyo, Japan

Site JP00002

Tochigi, Japan

Site JP00009

Hyogo, Japan

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo